Cromakalim

CAS No. 94470-67-4

Cromakalim( —— )

Catalog No. M33734 CAS No. 94470-67-4

Cromakalim (BRL 34915) is an ATP-dependent K(+) channel opener and a smooth muscle relaxant.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 44 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Cromakalim
  • Note
    Research use only, not for human use.
  • Brief Description
    Cromakalim (BRL 34915) is an ATP-dependent K(+) channel opener and a smooth muscle relaxant.
  • Description
    Cromakalim is a potassium channel opener. Cromakalim can be used as a bronchodilator in asthma. Cromakalim inhibits the spontaneous tone of human isolated bronchi in a concentration-related manner being nearly as effective as isoprenaline or theophylline.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Potassium Channel
  • Recptor
    Potassium Channel
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    94470-67-4
  • Formula Weight
    286.33
  • Molecular Formula
    C16H18N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 66.67 mg/mL (232.84 mM; Ultrasonic )
  • SMILES
    CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cortijo J, et al. The relaxant effects of cromakalim (BRL 34915) on human isolated airway smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1992;346(4):462-468.?
molnova catalog
related products
  • JNJ 303

    JNJ 303 is a potent blocker of IKs (IC50 : 64 nM).

  • Guangxitoxin 1E

    Guangxitoxin 1E acts as a gating modifier since it shifts the voltage-dependence of Kv2.1 K+ currents towards depolarized potentials.

  • Retigabine dihydroch...

    Retigabine dihydrochloride is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients.?The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels.In differentiated PC12 cells, retigabine enhanced a linopirdine-sensitive current.?